Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T21:55:50.015Z.
Calculation as of: 2026-10-06T21:55:50.015Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 271c6898cd70d4c389427987313f1838723d439a48fe58857c9b6a6cb9daa9ad
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$634.30M
EV/EBITDA Ratio
12.11x
TTM Avg
14.05x
3Y Avg
14.05x
5Y Avg
17.93x
Market Cap
$656.59M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aura Biosciences, Inc. (AURA) | $638.20M | N/A | N/A | N/A | N/A |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | 12.11x | 14.05x | 14.05x | 17.93x |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $630.63M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.59M | N/A | N/A | N/A | N/A |
| SOPHiA GENETICS S.A. (SOPH)vs › | $619.15M | N/A | N/A | N/A | N/A |
| Starling Oncology, Inc. (STLN)vs › | $657.89M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $660.29M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $611.57M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $666.95M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
